These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7898459)

  • 1. Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease.
    vanderSpek J; Cosenza L; Woodworth T; Nichols JC; Murphy JR
    Mol Cell Biochem; 1994 Sep; 138(1-2):151-6. PubMed ID: 7898459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting diphtheria toxin to growth factor receptors.
    Murphy JR; vanderSpek JC
    Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.
    Bacha P; Williams DP; Waters C; Williams JM; Murphy JR; Strom TB
    J Exp Med; 1988 Feb; 167(2):612-22. PubMed ID: 3126255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
    Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
    Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
    Grailer AP; Nichols JC; Strom TB; Sollinger HW; Burlingham WJ
    Cell Immunol; 1991 Feb; 132(2):481-93. PubMed ID: 1988163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.
    Waters CA; Schimke PA; Snider CE; Itoh K; Smith KA; Nichols JC; Strom TB; Murphy JR
    Eur J Immunol; 1990 Apr; 20(4):785-91. PubMed ID: 2140788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
    Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
    Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
    LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
    Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells.
    Kiyokawa T; Williams DP; Snider CE; Strom TB; Murphy JR
    Protein Eng; 1991 Apr; 4(4):463-8. PubMed ID: 1881872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells.
    Sweeney EB; Foss FM; Murphy JR; vanderSpek JC
    Bioconjug Chem; 1998; 9(2):201-7. PubMed ID: 9548535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic construction and characterization of the diphtheria toxin-related interleukin 15 fusion protein DAB389 sIL-15.
    vanderSpek JC; Sutherland J; Sampson E; Murphy JR
    Protein Eng; 1995 Dec; 8(12):1317-21. PubMed ID: 8869645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2.
    Zhang L; Waters C; Nichols J; Crumpacker C
    J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1181-7. PubMed ID: 1453329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of helix breaking mutations in the diphtheria toxin transmembrane domain helix layers of the fusion toxin DAB389IL-2.
    Hu HY; Huynh PD; Murphy JR; vanderSpek JC
    Protein Eng; 1998 Sep; 11(9):811-7. PubMed ID: 9796831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
    Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
    Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology.
    Foss FM
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S27-31. PubMed ID: 11707860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, cytotoxic properties and effects on early and late gene induction of a chimeric diphtheria toxin-leukemia-inhibitory factor protein.
    Negro A; Skaper SD
    Eur J Biochem; 1996 Oct; 241(2):507-15. PubMed ID: 8917449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
    Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
    Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
    Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG
    Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.